Basic Information
Landos Biopharma is dedicated to the research and development of novel drugs for combating autoimmune diseases. Landos' lead candidate drug, BT-11, is the first orally active and locally effective new drug, which can be used to treat Crohn's disease and ulcerative colitis.
Landos Biopharma, Inc.
Virginia,United States of America
15~50 people
January 01, 2017
info@landosbiopharma.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios